Outcomes Data of Adipose Stem Cells to Treat Multiple Sclerosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

221 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-05-31

Study Completion Date

2019-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the impact that treatment with a cellular concentrate derived from an individual's own fat, known as the stromal vascular fraction (SVF), has on the quality of life of people with multiple sclerosis (MS). SVF contains components with "regenerative" properties, including stem cells that may be capable of ameliorating specific disease conditions. This study is designed to evaluate quality of life changes in individuals with MS for up to 12 months following SVF treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis

NCT02326935

Multiple Sclerosis

TERMINATED PHASE1

Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis

NCT01453764

Multiple Sclerosis Autoimmune Diseases Autoimmune Diseases of the Nervous System +1 more

WITHDRAWN NA

Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study

NCT00273364

Multiple Sclerosis

COMPLETED PHASE2

Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis

NCT01056471

Autoimmune Diseases Immune System Diseases Demyelinating Diseases +3 more

COMPLETED PHASE1/PHASE2

Mesenchymal Stem Cells for Multiple Sclerosis

NCT01730547

Multiple Sclerosis

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects scheduled for a stem cell/SVF treatment
* Subjects diagnosed with some form of multiple sclerosis
* Subjects between the ages of 18 and 65
* Subjects willing and able to sign informed consent
* Subjects willing and able to perform follow up interviews and surveys